Joint Clinical Trials Office
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Comparison of Venipuncture Serum Prostate Specific Antigen (PSA) with Point of Care Fingerstick Blood Draw Rapid Test for PSA (RT-PSA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Liquid Biopsy for Longitudinal Monitoring in Diffuse Midline Glioma (DMG) Patients
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated with H. pylori Infection and Gastric Cancer Carcinogenesis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Phase II study of Polatuzumab vedotin in combination with chemotherapy in subjects with Richter’s Transformation
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia or High-risk myelodysplasia
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Blood Coagulation in Cancer Patients
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
A multiomics profiling study to classify the origin of Cancers of Unknown Primary (CUP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023